Shares of Achaogen (NASDAQ:AKAO) have been assigned an average recommendation of “Buy” from the thirteen analysts that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and ten have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $23.29.

Several brokerages have issued reports on AKAO. ValuEngine raised shares of Achaogen from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. Zacks Investment Research cut shares of Achaogen from a “hold” rating to a “sell” rating in a report on Monday, February 5th. Guggenheim reaffirmed a “buy” rating and issued a $14.00 target price on shares of Achaogen in a report on Wednesday, January 10th. Mizuho reaffirmed a “buy” rating and issued a $28.00 target price on shares of Achaogen in a report on Wednesday, January 3rd. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $20.00 target price (down from $29.00) on shares of Achaogen in a report on Wednesday, February 28th.

NASDAQ:AKAO traded down $0.10 during mid-day trading on Friday, hitting $13.02. 545,160 shares of the company’s stock were exchanged, compared to its average volume of 1,217,316. Achaogen has a one year low of $9.83 and a one year high of $27.49. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.83 and a quick ratio of 4.83. The firm has a market capitalization of $585.43, a P/E ratio of -4.07 and a beta of 1.04.

Achaogen (NASDAQ:AKAO) last posted its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.21). The business had revenue of $1.87 million for the quarter, compared to the consensus estimate of $1.18 million. Achaogen had a negative return on equity of 83.14% and a negative net margin of 1,124.10%. equities research analysts expect that Achaogen will post -3.48 earnings per share for the current fiscal year.

In other news, insider Kenneth J. Hillan sold 2,735 shares of the business’s stock in a transaction that occurred on Tuesday, March 13th. The shares were sold at an average price of $11.74, for a total transaction of $32,108.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Robert W. Duggan acquired 10,000 shares of the firm’s stock in a transaction dated Wednesday, February 14th. The shares were bought at an average cost of $10.96 per share, with a total value of $109,600.00. Following the completion of the acquisition, the insider now directly owns 5,668,310 shares of the company’s stock, valued at $62,124,677.60. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 1,398,754 shares of company stock valued at $16,383,570 and have sold 10,089 shares valued at $110,576. 8.36% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. MetLife Investment Advisors LLC purchased a new position in shares of Achaogen during the fourth quarter valued at approximately $151,000. Iguana Healthcare Management LLC raised its holdings in shares of Achaogen by 150.0% during the fourth quarter. Iguana Healthcare Management LLC now owns 75,000 shares of the biopharmaceutical company’s stock valued at $806,000 after purchasing an additional 45,000 shares during the last quarter. DSC Advisors L.P. purchased a new position in shares of Achaogen during the fourth quarter valued at approximately $752,000. Teachers Advisors LLC raised its holdings in shares of Achaogen by 15.0% during the fourth quarter. Teachers Advisors LLC now owns 62,483 shares of the biopharmaceutical company’s stock valued at $671,000 after purchasing an additional 8,137 shares during the last quarter. Finally, Two Sigma Investments LP bought a new stake in Achaogen during the fourth quarter valued at approximately $260,000. 77.41% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This article was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.thecerbatgem.com/2018/04/25/analysts-set-achaogen-akao-pt-at-23-29.html.

Achaogen Company Profile

Achaogen, Inc, a late-stage biopharmaceutical company, focusses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae.

Analyst Recommendations for Achaogen (NASDAQ:AKAO)

Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.